ABOUT US

ABOUT US

OUR MISSION

Our mission is to develop a breakthrough medical device for the most urgent healthcare issues. Focusing on patients’ needs, we translate the most promising research to clinical application. We primarily focus on finding a targeted and efficient therapy for patients with sepsis, a devastating condition causing millions of deaths annually.

What started within the Functional Materials Laboratories of ETH Zurich soon developed to a growing company determined to develop life-saving therapies and change the world of medical technology.

 
TEAM
Lukas Langenegger, CEO

lukas.langenegger@hemotune.ch

Lukas is one of the founders of hemotune. He is deeply passionate to work at the interface between economics and research and to bring life-saving technologies from the research bench to the clinics. After completing a banking apprenticeship and working for 2 years at UBS, Lukas decided to follow his passion and studied Chemical and Bioengineering at ETH Zurich and MIT. Lukas holds a M.Sc. degree in Chemical and Bioengineering from ETH Zurich and a diploma from the Swiss Bankers Association.

Dr. Carlos Mora, CSO

carlos.mora@hemotune.ch

Carlos is one of the founders of hemotune. With his very interdisciplinary background in microbiology, immunology and bioengineering he perfectly complements the hemotune team. During his studies at ETH Zurich, Carlos focused on the behavior and interaction of magnetic and non-magnetic nanoparticles in biological systems. He holds a Ph.D. degree in Chemical- and Bioengineering and an M.Sc. degree in Microbiology and Immunology, both from ETH Zurich, Switzerland.

Dr. Jean-Claude Metzger, Head of Product Development

jean-claude.metzger@hemotune.ch

Jean-Claude Metzger has joined hemotune in December 2017 as Head of Product Development, leading the development of hemotune’s blood purification device. Before joining hemotune, he was responsible for hardware development of a post-analytics device for in-vitro diagnostics heading a team of engineers as Department Project Leader at Roche Diagnostics. Jean-Claude holds both an MSc and Ph.D. in Mechanical Engineering from ETH Zurich.

Dr. Ursina Haltinner, Regulatory & Quality Manager

ursina.haltinner@hemotune.ch

Ursina Haltinner joined hemotune in October 2018 as Regulatory and Quality Affairs Manager. Ursina brings along 10 years of experience in the health care industry. She started her career as regulatory affairs manager in the product development center of Synthes GmbH. Besides the medical device industry, she also provided regulatory support to biotechnology and pharmaceutical companies, taking care of the main markets such as the US and EU. Ursina holds a doctoral degree in veterinary medicine from Vetsuisse Faculty, Zurich.

Dr. Manuel Baumgartner, R&D Engineer

manuel.baumgartner@hemotune.ch

Manuel Baumgartner joined hemotune in November 2018 as an R&D Engineer. Manuel obtained his Ph.D. in Materials Science from ETH Zurich, where he worked on nanomagnetism and spintronics devices. At hemotune he supports the device development team, focusing on testing and measuring magnetic nanoparticles. His doctoral thesis was nominated for the 2018 ETH Medal for outstanding PhD work.

Lorenz Poiger, R&D Engineer

lorenz.poiger@hemotune.ch

Lorenz Poiger joined hemotune in March 2019 as an R&D Engineer. Lorenz holds a Bachelor’s degree from ZHAW in Mechanical Engineering majoring in Biomechanical Engineering. Throughout his studies he has developed and tested a lumbar spine disc implant for a customer in the medical field and gained experiences in product development including prototyping and manufacturing.

INNOSUISSE RESEARCH PARTNER TEAM
Dr. Inga Nilsson, R&D Chemist

inga.nilsson@hemotune.ch

Inga Nilsson works at Wyss Zurich as part of an Innosuisse project with hemotune  as an R&D Chemist. Inga holds a Ph.D. in Chemistry from the University of Rostock in Germany, where she focused on the multi-step synthesis of biologically relevant oligosaccharides. Before joining this project, Inga worked as a postdoctoral fellow at the Novartis Institute for Biomedical Research in Emeryville, California, where she gainedexperience in bacteriology, chemical biology, and assay development. With her knowledge of organic synthesis and biological applications, she assists in the development of the nanomagnets, including synthesis and functionalization.

Dr. Monika Dengler, Biomedical Scientist

monika.dengler@hemotune.ch

Monika Dengler works at Wyss Zurich as part of an Innosuisse project with hemotune as a Biomedical Scientist. She is involved in the product development of the nanomagnets, thereby managing the preclinical functional performance and biocompatibility studies. Monika obtained her Ph.D. in Pharmaceutical Sciences from ETH Zurich, where she worked on liver enzymes relevant to xenobiotic metabolism. During her studies, Monika completed a series of toxicology courses and gained considerable expertise in molecular, cellular, and clinical toxicology, risk assessment, and safety pharmacology.

Lukas Huber, Chemical Process Engineer

lukas.huber@hemotune.ch

Lukas Huber works at Wyss Zurich as part of an Innosuisse project with hemotune. As a Chemical Process Engineer he assists in the development and production of the nanomagnets. Before joining this project, Lukas worked at Empa, where he was responsible for the pyrolysis and activation of nitrogen-doped carbon xerogels, as well as for the upscaling of silica aerogels from lab scale to pilot scale. Lukas holds a Master's degree from ETH Zurich in Materials Science.

BOARD OF DIRECTORS
Didier Cowling

President of the Board

Didier Cowling joined hemotune as President of the Board of Directors in 2019. He started his career as an investment analyst, first at Nomura and then at HSBC, forming a highly rated pharma and medtech team. He then moved into industry to be Director of Business Development at Phairson Medical Ltd. In 2000, he co-founded Kuros Therapeutics AG, which was successfully sold in 2002. Subsequently, he co-founded Kuros Biosurgery AG, which worked on developing a number of drug/device combination products. In early 2016, Kuros Biosurgery merged with Cytos Biotechnology and was renamed Kuros Biosciences AG, becoming public on the Swiss Exchange. Didier retired as President & CEO of the Kuros group in 2018 and is now working with a number of SMEs in the life science space, helping them to form and grow, both as an advisor and at Board level. As a serial entrepreneur and board member with over 30 years of broad experience in the field, Didier brings to hemotune his deep knowledge of the medtech industry and hands-on start-up experience.

Perry van Rijsingen

Board Member

Perry van Rijsingen, through his company “21st Century Business Growth Advisors”, is Adviser, Independent Board Member, Horizon 2020 Business Coach and interim CEO. He also provides strategic advice to the Dutch high-tech company Sioux to help them develop their Healthcare business. In 2019 he joined the Board of Directors of Hemotune as Independent Board Member. Before, Perry was CEO of 2 large businesses at Philips and was responsible for Philips corporate venturing for 10 years, reporting directly to its Board of Management. In this latter role he led, commercialized & coached many start-ups & scale-ups in healthcare. In the process, he created new business models, markets & eco-systems, yielding triple digit growth and significant strategic & enterprise value for Philips. Perry, following his 35 years career, provides perspective beyond the textbooks. And he is one of the few international executives with a strong track record of successful leadership, innovation, commercialization and strategy in large/mature businesses and start-ups, with a deep understanding of how to succeed in both worlds. He brings deep knowledge in Medtech and Big Data.

Lukas Langenegger

CEO, Board Member

Dr. Carlos Mora

CSO, Board Member

ADVISORS
Prof. Dr. Wendelin Jan Stark

PhD, ETH Zurich

Prof. Stark is a leading scientist in the field of nanotechnology and is currently Professor at the Institute of Chemical and Bioengineering and head of the Functional Materials Laboratory at ETH Zurich. He has published about 300 scientific articles and is co-founder of several spin off companies.

Prof. Dr. Robert Grass

PhD, Turbobeads GmbH

Prof. Grass is an expert in development and manufacturing of magnetic nanoparticles he is co-founder and CEO of turbobeads PLC, which manufactures and sells magnetic nanoparticles for research and industrial applications. He is also Professor at ETH Zurich.

Prof. Dr. Inge Herrmann

PhD, EMPA & ETH Zurich

Prof. Herrmann is an expert in medical applications of magnetic nanoparticles. She has authored several publications in magnetic blood purification and is currently group leader at the Swiss Federal Laboratories for Material Science and Technnology (EMPA) and Assistant Professor at ETH Zurich.

OUR VISION

We envision a future where the deep understanding of diseases allows targeted interventions for the most challenging medical needs. By being technology leaders in highly specific blood purification, hemotune provides the means to treat critically ill patients and save lives.

Invest in a life-saving therapy.

You want to know more about our innovation?

© 2020 by hemotune

  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon

created by wyssraumdesign